Voltage-gated sodium channels in peripheral nociceptive neurons (VGSCs)

Voltage-gated sodium channels (VGSCs) in peripheral nociceptive neurons, specifically the NaV1.7, NaV1.8, and NaV1.9 isoforms, are essential components of the pain signaling pathway [2, 3, 5]. These channels act as molecular switches that initiate and propagate electrical signals (action potentials) from peripheral tissues to the central nervous system in response to noxious stimuli [1, 13]. NaV1.7 serves as a threshold-setting channel that amplifies subthreshold stimuli, while NaV1.8 is responsible for the majority of the inward current during the action potential upstroke in nociceptors, and NaV1.9 modulates resting membrane potential and subthreshold excitability [9, 11, 20]. Mutations in the genes encoding these channels (SCN9A, SCN10A, and SCN11A) are directly linked to human pain disorders, including inherited erythromelalgia and congenital insensitivity to pain, validating them as high-value therapeutic targets [12, 15, 19]. Modern drug discovery efforts focus on developing isoform-selective inhibitors, such as the NaV1.8-selective blocker suzetrigine (VX-548), to provide potent analgesia for acute and chronic pain without the central nervous system side effects or addiction risks associated with traditional opioids [4, 6, 17].

Other names

Peripheral nociceptive sodium channelsSodium channel protein type 9 subunit alphaSodium channel protein type 10 subunit alphaSodium channel protein type 11 subunit alphaNaV1.7NaV1.8NaV1.9SCN9ASCN10ASCN11A

Selective inhibition of voltage-gated sodium channel isoforms (primarily NaV1.7, NaV1.8, or NaV1.9) to stabilize the channel in its closed or inactivated state, thereby preventing the influx of sodium ions and the subsequent generation or propagation of action potentials in nociceptive neurons [1, 4, 6, 11].